Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Real-time Estimate Cboe BZX
Other stock markets
 12:43:32 2024-06-11 pm EDT 		5-day change 1st Jan Change
12.64 USD +3.48% Intraday chart for Viridian Therapeutics, Inc. +7.93% -42.52%
03:12pm Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
02:53pm Sector Update: Health Care MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT
Sector Update: Health Care
MT
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins
MT
Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target
MT
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket
MT
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target
MT
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
BU
Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
BU
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25
MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating
MT
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000
MT
Transcript : Viridian Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.